title: Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD, or MBVD.
abstract: From January 1986 to December 1989, 157 previously untreated patients, with Hodgkin's disease stage I or II without bulky disease, were enrolled in a clinical comparative study. The objectives of the study were to compare the efficacy and safety of using epirubicine or mitoxantrone instead of adriamycin in the combination chemotherapy regimen ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine). The complete response rate was better in the patients treated with the ABVD or EBVD regimens compared to the MBVD arm. Also, differences in overall survival and relapse-free survival were better in the patients who received ABVD or EBVD compared to the MBVD regimen. Hematological, gastrointestinal and cardiac toxicity were similar in the three groups. Dose intensity, delays and complications were also similar in the three groups. The mitoxantrone-containing regimen was found to have less efficacy in comparison to the other regimens tested in the present study in patients with favorable stage I or II Hodgkin's disease.
authors.affiliation: Department of Hematology, Oncology Hospital, National Medical Center, Mexico City, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: B
authors.initials: B
authors.lastname: Soto
authors.forename: R
authors.initials: R
authors.lastname: Guzmán
authors.forename: E L
authors.initials: EL
authors.lastname: García
authors.forename: M J
authors.initials: MJ
authors.lastname: Nambo
authors.forename: J C
authors.initials: JC
authors.lastname: Díaz-Maqueo
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D009367:Neoplasm Staging; D012074:Remission Induction; D015996:Survival Rate; D014747:Vinblastine; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D015251:Epirubicin; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D008942:Mitoxantrone